Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apabetalone - Resverlogix Corporation

Drug Profile

Apabetalone - Resverlogix Corporation

Alternative Names: RVX-000222; RVX-208

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Antidementias; Antihyperlipidaemics; Antihypertensives; Antiretrovirals; Antivirals; Cardiovascular therapies; Ethers; Ketones; Nootropics; Quinazolines; Small molecules; Urologics; Vascular disorder therapies
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol; Vascular dementia
  • Phase II/III COVID 2019 infections
  • Phase II Prediabetic state
  • No development reported Alzheimer's disease; Fabry's disease; HIV infections; Pulmonary arterial hypertension; Renal failure

Most Recent Events

  • 18 Nov 2023 Resverlogix terminates a phase II/III trial in COVID-2019 infections (Adjunctive treatment) in Brazil and Canada (PO), due to unable to recruit patients (NCT04894266)
  • 25 Aug 2023 Pharmacodynamics data from a preclinical studies in Cardiometabolic disease presented at the at the Annual Congress of the European Society of Cardiology (ESC-Card-2023)
  • 28 Apr 2023 No recent reports of development identified for preclinical development in Fabry's-disease in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top